- Home
- BORR vs COLL Comparison
BORR vs COLL Comparison
Compare BORR & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BORR
- COLL
- Stock Information
- Founded
- BORR 2016
- COLL 2002
- Country
- BORR Bermuda
- COLL United States
- Employees
- BORR N/A
- COLL N/A
- Industry
- BORR Oil & Gas Production
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- BORR Energy
- COLL Health Care
- Exchange
- BORR Nasdaq
- COLL Nasdaq
- Market Cap
- BORR 941.4M
- COLL 910.2M
- IPO Year
- BORR 2019
- COLL 2015
- Fundamental
- Price
- BORR $2.20
- COLL $29.63
- Analyst Decision
- BORR Buy
- COLL Strong Buy
- Analyst Count
- BORR 1
- COLL 5
- Target Price
- BORR $9.00
- COLL $43.60
- AVG Volume (30 Days)
- BORR 7.0M
- COLL 353.2K
- Earning Date
- BORR 02-19-2025
- COLL 02-27-2025
- Dividend Yield
- BORR 3.63%
- COLL N/A
- EPS Growth
- BORR 255.56
- COLL 43.56
- EPS
- BORR 0.32
- COLL 1.86
- Revenue
- BORR $1,010,600,000.00
- COLL $631,449,000.00
- Revenue This Year
- BORR $8.35
- COLL $19.43
- Revenue Next Year
- BORR $6.39
- COLL $3.34
- P/E Ratio
- BORR $7.31
- COLL $15.84
- Revenue Growth
- BORR 30.97
- COLL 11.41
- 52 Week Low
- BORR $2.17
- COLL $27.28
- 52 Week High
- BORR $7.26
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- BORR 26.01
- COLL 49.02
- Support Level
- BORR $2.17
- COLL $28.37
- Resistance Level
- BORR $2.44
- COLL $30.04
- Average True Range (ATR)
- BORR 0.17
- COLL 1.31
- MACD
- BORR -0.02
- COLL 0.18
- Stochastic Oscillator
- BORR 2.93
- COLL 56.54
About BORR Borr Drilling Limited
Borr Drilling Ltd is a drilling contractor that owns and operates jack-up rigs of modern and high-specification designs providing drilling services to the oil and gas exploration and production industry. The company operates a fleet of around 16 jack-up drilling rigs. Geographically the activities are carried out through Norway.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.